



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/522356-Conf. #1380		
		Filing Date	January 26, 2005		
		First Named Inventor	Christopher Bruce A.		
		Art Unit	1645		
		Examiner Name	Not Yet Assigned		
Sheet	1	of	2	Attorney Docket Number	0102286.00155US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
SW	AA*	US-5,948,677	09-07-1999	Jarvik	
SW	AB*	US-6,114,123	09-05-2000	Murry et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
SW	BA	CA-2376638-A1	12-14-2000	Skerra		
	BB	EP-1111387-A1	06-27-2001	Maruha Corporation et al.		
	BC	EP-1130086-A1	09-05-2001	Deutsches Krebsforschungszentrum et al.		
	BD	WO-PCT/GB03/03192		Roslin Institute		
	BE	WO-97/07132	02-27-1997	Commonwealth Scientific and Industrial Research Organisation		
	BF	WO-98/30715	07-16-1998	California Institute of Technology		
	BG	WO-99/37142	07-29-1999	Novo Nordisk		
	BH	WO-00/75308-A1	12-14-2000	Skerra		
	BI	WO-02/01949-A2	01-10-2002	Universita' Deglistudi Di Milano		
	BJ	WO-02/31151-A2	04-18-2002	Invyte Genomics, Inc.		
SW	BK	WO-02/053701-A2	07-11-2002	Vanderbilt University		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
gm	CA	CROSSETT et al., "Transfer of a Uterine Lipocalin from the Endometrium of the Mare to the Developing Equine Conceptus", <i>Biology of Reproduction</i> , Vol 59, pp. 483-490, 1998				
	CB	MCCLLENAGHAN et al., "Insertion of a casein kinase recognition sequence induces phosphorylation of ovine β -lactoglobulin in transgenic mice", <i>Protein Engineering</i> , Vol. 12, No. 3, pp. 259-264, 1999				
	CC	NILSSON et al., "An in vivo mouse reportr gene (human secreted alkaline phosphatase) model to monitor ovarian tumor growth and response to therapeutics", <i>Cancer Chemother Pharmacol</i> , Vol. 49, pp. 93-100, 2002				
	CD	SCHLEHUBER et al., "A Novel Type of Receptor Protein, Based on the Lipocalin Scaffold, with Specificity for Digoxigenin", <i>JMB</i> , pp. 1105-1120, 2000				
	CE	SCHMIDT et al., "A Zn(II)-binding site engineered into retinol-binding protein exhibits metal-ion specificity and allows highly efficient affinity purification with a newly designed metal ligand", <i>Chemistry & Biology</i> , Vol. 3, No. 8, pp. 645-653, 1996				
gm	CF	SUI et al., "Interaction of Insulin-like Growth Factor Binding Protein-4, Miz-1, Leptin, Lipocalin-				

Examiner Signature	<i>SW</i>	Date Considered	12-4-07
--------------------	-----------	-----------------	---------

5525261


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/522356-Conf. #1380
				Filing Date	January 26, 2005
				First Named Inventor	Christopher Bruce A.
				Art Unit	1645
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	0102286.00155US1

		Type Prostaglandin D Synthase, and Granulin Precursor with the N-Terminal Half of Type III Hexokinas", <i>Archives of Biochemistry and Biophysics</i> , Vol. 382, No. 2, pp. 262-274, 15 OCTober 2000	
	CG	SUNDARAM et al., "Expression, characterization and engineered specificity of rat epididymal rdtinoic acid-binding protein", <i>Biochem. J.</i> , Vol. 334, pp. 155-160, 1998	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	12-4-07
-----------------------	---	--------------------	---------